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circulating but not faecal short-
chain fatty acids are related to 
insulin sensitivity, lipolysis and 
GLP-1 concentrations in humans
Mattea Müller  1, Manuel A. González Hernández1, Gijs H. Goossens1, Dorien Reijnders2, 
Jens J. Holst3, Johan W. e. Jocken1, Hans van eijk  4, Emanuel E. canfora  1 & ellen e. Blaak  1
Microbial-derived short-chain fatty acids (SCFA) acetate, propionate and butyrate may provide a link 
between gut microbiota and whole-body insulin sensitivity (IS). In this cross-sectional study (160 
participants, 64% male, BMI: 19.2–41.0 kg/m2, normal or impaired glucose metabolism), associations 
between SCFA (faecal and fasting circulating) and circulating metabolites, substrate oxidation and 
iS were investigated. in a subgroup (n = 93), IS was determined using a hyperinsulinemic-euglycemic 
clamp. Data were analyzed using multiple linear regression analysis adjusted for sex, age and BMI. 
fasting circulating acetate, propionate and butyrate concentrations were positively associated with 
fasting GLP-1 concentrations. Additionally, circulating SCFA were negatively related to whole-body 
lipolysis (glycerol), triacylglycerols and free fatty acids levels (standardized (std) β adjusted (adj) 
−0.190, P = 0.023; std β adj −0.202, P = 0.010; std β adj −0.306, P = 0.001, respectively). Circulating 
acetate and propionate were, respectively, negatively and positively correlated with IS (M-value: std β 
adj −0.294, P < 0.001; std β adj 0.161, P = 0.033, respectively). We show that circulating rather than 
faecal SCFA were associated with GLP-1 concentrations, whole-body lipolysis and peripheral IS in 
humans. Therefore, circulating SCFA are more directly linked to metabolic health, which indicates the 
need to measure circulating SCFA in human prebiotic/probiotic intervention studies as a biomarker/
mediator of effects on host metabolism.
In obesity and type 2 diabetes mellitus (T2DM), alterations in the gut microbiota composition and functionality 
may contribute to disease aetiology. The gut microbiota ferments indigestible carbohydrates (e.g. dietary fibres) 
and major end-products thereof are the short- chain fatty acids (SCFA) acetate, propionate and butyrate1. Acetate, 
propionate and butyrate are present in the colon in a ratio of approximately 3:1:1, respectively2,3. Most butyrate is 
utilized by colonocytes as energy source4. Via the portal vein, SCFA reach the liver where acetate and propionate 
are metabolized and partly oxidised or used as substrate in gluconeogenesis and lipogenesis5. Consequently, a 
small proportion of microbial-derived SCFA enters the peripheral circulation whereby acetate reaches the highest 
concentrations compared to propionate and butyrate6,7. SCFA are ligands to G-protein coupled receptors (GPR) 
41 and 43, which are expressed on intestinal, adipose, skeletal muscle, liver and pancreatic tissues8–10, indicat-
ing their important role in the crosstalk between the gut and peripheral tissues. Several rodent studies showed 
that oral, intravenous and colonic infusion of SCFA as well as microbial-derived SCFA beneficially affect the 
functioning and metabolism of the aforementioned tissues and consequently improve insulin sensitivity, sub-
strate metabolism and body weight regulation11. In humans, distal colonic acetate infusions increased fasting fat 
oxidation, energy expenditure, and peptide YY (PYY) secretion whilst whole-body lipolysis was decreased12,13. 
Other acute studies show decreased circulating free fatty acid (FFA) concentration after rectal SCFA infusion in 
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healthy participants14,15. In addition, 24 weeks of 10 g/day inulin propionate ester protected against body weight 
gain as compared to inulin only in overweight individuals16. Potential mechanisms may include a SCFA-induced 
inhibition of energy intake possibly mediated via the stimulation of glucagon-like peptide 1 (GLP-1) and PYY 
secretion, increased intestinal gluconeogenesis, increased skeletal muscle fat oxidation and improved lipid buff-
ering capacity of adipose tissue11. However, increased microbial-derived acetate formation has been associated 
with increased body weight gain and insulin resistance in diet-induced obese rats17. Additionally, increased faecal 
SCFA have been reported in overweight and obese compared to lean participants2,3,8,18,19, yet it is difficult to inter-
pret the latter data since faecal SCFA reflect the net result of colonic production and absorption20,21. Even though 
faecal SCFA are commonly used as an indicator of microbial fermentation, faecal SCFA may not accurately reflect 
in vivo colonic fermentation since approximately 95% of colonic SCFA are absorbed and only the remaining 5% 
are excreted in feces22–25.
To obtain more information on the validity of faecal SCFA as biomarker for metabolic health effects, the asso-
ciations between faecal and circulating SCFA concentrations and parameters of metabolic health were studied in 
a relatively large cohort of 160 participants with a wide range of body mass indices (BMI) and glucometabolic sta-
tus. Using multiple regression analysis, we analysed the relationship between faecal and fasting circulating SCFA 
with fasting glucose, insulin, circulating lipids (free fatty acids (FFA), triacylglycerols (TAG), glycerol), insulin 
resistance index (homeostasis model assessment of insulin resistance (HOMA-IR)), gut hormone concentrations 
(PYY, GLP-1), fasting substrate utilization and inflammation markers including lipopolysaccharide-binding pro-
tein (LBP), tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and interleukin 8 (IL-8). We further inves-
tigated the relationship between faecal and fasting circulating SCFA profiles and peripheral insulin sensitivity 
index (M-value) as measured via the gold standard hyperinsulinaemic-euglycemic clamp technique.
Results
Mean age of the participants was 49.6 ± 14.7 years and 66.2% of participants were male with a mean BMI of 
29.8 ± 4.4 kg/m2, a mean fasting glucose of 5.6 ± 0.6 mmol/L and a mean HOMA-IR of 3.7 ± 1.5 (Table 1). In the 
subgroup, peripheral (M-value) was measured in 93 overweight to obese, prediabetic men (n = 72) and women 
(n = 21) with mean age of 59.0 ± 7.1 years and a mean BMI of 31.8 ± 3.1 kg/m2, respectively.
Associations between faecal and circulating ScfA concentrations. Faecal acetate and butyrate 
were not associated to their respective circulating concentrations, while faecal propionate was positively associ-
ated with circulating propionate (standardized (std) std β = 0.262, P = 0.002).
circulating, but not faecal, ScfA are associated with BMi. Faecal acetate was positively associated 
with BMI (std β = 0.245, P = 0.004), however, after adjustment for age and sex, the association was not signif-
icant anymore (std β adj = 0.092, P = 0.214). Faecal propionate and butyrate were not significantly associated 
Characteristic Mean ± SD Range
Male (n)/Female (n) 106/54
Age (y) 49.6 ± 14.7 20–69
Body Weight (kg) 90.8 ± 15.7 52.8–125.9
BMI (kg/m2) 29.8 ± 4.4 19.2–41.0
Waist:Hip ratio 0.93 ± 0.13 0.64–1.22
HOMA-IR 3.7 ± 1.5 1.0–9.0
Fasting plasma insulin (mU/L) 14.9 ± 9.4 2.4–82.7
Fasting plasma glucose (mmol/L) 5.6 ± 0.6 3.1–7.5
Fasting plasma free fatty acids (μmol/L) 672 ± 243 140.3–1620
Fasting plasma triacylglycerol (μmol/L) 1178 ± 613 311.0 – 3944
Fasting free glycerol (μmol/L) 102.1 ± 46 27.1–372.1
Plasma acetate (μmol/L) 65.2 ± 64.7 2.8–429.4
Plasma propionate (μmol/L) 2.0 ± 1.6 0.06–12.0
Plasma butyrate (μmol/L) 1.7 ± 1.8 0.07–6.7
Faecal acetate (μmol/g) 44.2 ± 16.1 6.80–102.8
Faecal propionate (μmol/g) 13.0 ± 7.9 2.53–71.2
Faecal butyrate (μmol/g) 10.9 ± 5.9 0.00–33.8
Subgroup hyperinsulinaemic-euglycaemic clamp
Male (n) /Female (n) 72/21
BMI (kg/m2) 31.8 ± 3.1 26.1–41
Age (y) 59.0 ± 7.1 72–69
Fasting glucose (mmol/L) 6.0 ± 0.5 5.0–7.5
2 h glucose (mmol/L) 7.2 ± 1.8 3.3–11.2
M-value (mg*kg−1*min−1) 3.6 ± 1.5 1.7–8.3
Table 1. Characteristics of participants. BMI body mass index, HOMA-IR Homeostasis model assessment of 
insulin resistance, M-value mean glucose infusion rate at steady state during insulinemic- euglycemic clamps.
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with BMI with or without adjustment for age and sex (faecal butyrate std β = 0.162, P = 0.055, faecal propionate 
std β = 0.023, P = 0.746). In contrast, circulating butyrate and propionate were significantly inversely related to 
BMI, also after adjustment for age and sex (circulating butyrate std β = −0.599, P < 0.001, circulating propionate 
std β = −0.290, P < 0.001, Supplementary Figure 1 K,L). Circulating acetate was negatively associated with BMI 
(std β = −0.285, P < 0.001), which was not significant anymore after adjustment for age and sex (std β = −0.115, 
P = 0.108).
Faecal SCFA were not related to metabolic parameters. None of faecal SCFA were significantly asso-
ciated with fasting GLP-1, PYY, FFA, TAG, glycerol, glucose, insulin concentrations, HOMA-IR, inflammatory 
markers or fasting substrate oxidation either with or without adjustment for age, sex and BMI. In the subgroup 
analysis faecal SCFA were not associated with peripheral insulin sensitivity (Table 2).
Fasting, circulating SCFA were related to fasting GLP-1, lipid metabolites and insulin sensi-
tivity. All three circulating SCFA were positively associated with fasting GLP-1 concentrations (Table 3). 
Additionally, circulating acetate, propionate and butyrate were negatively associated with fasting glycerol, TAG 
and FFA, respectively. Also, circulating butyrate was negatively associated with fasting glucose. These relation-
ships remained significant after adjustment for age, sex and BMI (Table 3, Supplementary Figure 1).
Circulating SCFA were not associated with fasting PYY, LBP, IL-6, IL-8 and TNF-α. Furthermore, circulat-
ing SCFA were not related to fat and carbohydrate oxidation, expressed as percentage of energy expenditure. In 
the subgroup analysis of overweight/obese, prediabetic individuals, peripheral insulin sensitivity was measured 
using the M-value derived from the euglycemic-hyperinsulinaemic clamp technique. We found that circulating 
acetate was negatively associated with peripheral insulin sensitivity (M-value) whereas circulating propionate was 
positively related to peripheral insulin sensitivity (Table 3, Supplementary Figure 1). The relationships between 
circulating SCFA and insulin sensitivity remained significant after adjustment for age, sex and BMI.
Discussion
We investigated the relationship between faecal and fasting circulating SCFA with fasting plasma metabolites, gut 
hormones, substrate metabolism and inflammatory markers in a cohort with a wide range of BMI and glucomet-
abolic status. This study shows that only circulating but not faecal SCFA concentrations were related to fasting 
plasma glucose, FFA, TAG and glycerol, GLP-1 and insulin sensitivity, also after adjustment for age, sex and BMI. 
Metabolites
Faecal acetate Faecal propionate Faecal butyrate
std ß P std β adj P std ß P std β adj P std ß P std β adj P
FFA, μmol/L 0.052 ± 0.090 0.569 −0.048 ± 0.082 0.558 −0.098 ± 0.089 0.276 −0.092 ± 0.080 0.249 0.001 ± 0.090 0.991 −0.030 ± 0.081 0.707
TAG, μmol/L 0.058 ± 0.090 0.519 −0.057 ± 0.084 0.498 0.129 ± 0.089 0.151 0.037 ± 0.081 0.647 0.094 ± 0.090 0.296 −0.007 ± 0.082 0.931
Glycerol, μmol/L −0.047 ± 0.090 0.603 −0.152 ± 0.086 0.079 −0.019 ± 0.090 0.836 −0.022 ± 0.084 0.797 −0.185 ± 0.145 0.205 −0.160 ± 0.084 0.059
Hormones
Insulin, mU/L 0.275 ± 0.082 0.001 0.122 ± 0.071 0.088 0.185 ± 0.084 0.029 0.114 ± 0.069 0.101 0.207 ± 0.084 0.015 0.102 ± 0.070 0.146
GLP-1, pmol/L −0.081 ± 0.092 0.379 0.114 ± 0.074 0.125 0.017 ± 0.092 0.852 0.140 ± 0.071 0.053 −0.037 ± 0.092 0.692 0.116 ± 0.072 0.113
PYY, pmol/L −0.194 ± 0.106 0.070 −0.166 ± 0.112 0.140 −0.093 ± 0.107 0.386 −0.087 ± 0.110 0.428 −0.156 ± 0.106 0.146 −0.142 ± 0.110 0.199
Insulin sensitivity
M-value, mg/
kg/min −0.071 ± 0.106 0.502 −0.035 ± 0.075 0.640 −0.029 ± 0.105 0.783 −0.050 ± 0.073 0.490 −0.100 ± 0.105 0.345 −0.111 ± 0.073 0.130
HOMA-IR 0.267 ± 0.084 0.002 0.080 ± 0.068 0.244 0.193 ± 0.085 0.025 0.091 ± 0.066 0.169 0.214 ± 0.085 0.013 0.076 ± 0.067 0.254
Glucose, 
mmol/L 0.174 ± 0.084 0.040 −0.029 ± 0.067 0.661 0.112 ± 0.084 0.187 0.006 ± 0.065 0.925 0.086 ± 0.085 0.310 −0.066 ± 0.066 0.315
Inflammatory markers
LBP, pg/ml 0.152 ± 0.091 0.095 0.033 ± 0.086 0.699 0.024 ± 0.091 0.789 −0.010 ± 0.084 0.909 0.155 ± 0.090 0.088 0.092 ± 0.084 0.274
IL-6, pg/ml 0.164 ± 0.085 0.055 −0.010 ± 0.071 0.892 0.012 ± 0.085 0.887 −0.088 ± 0.069 0.204 0.039 ± 0.085 0.651 −0.094 ± 0.069 0.178
IL-8, pg/ml 0.157 ± 0.085 0.067 0.106 ± 0.088 0.231 0.164 ± 0.084 0.053 0.118 ± 0.085 0.170 0.115 ± 0.085 0.179 0.061 ± 0.086 0.479
TNF-α, pg/ml 0.196 ± 0.084 0.021 0.070 ± 0.078 0.170 0.063 ± 0.085 0.459 −0.046 ± 0.076 0.548 0.156 ± 0.084 0.067 0.039 ± 0.076 0.612
Substrate Oxidation
Fat, E% 0.036 ± 0.092 0.691 0.001 ± 0.095 0.996 −0.002 ± 0.091 0.982 0.004 ± 0.093 0.970 0.013 ± 0.092 0.885 0.004 ± 0.094 0.969
CHO, E % −0.092 ± 0.094 0.329 −0.084 ± 0.098 0.397 −0.034 ± 0.094 0.716 −0.042 ± 0.096 0.666 −0.110 ± 0.094 0.243 −0.116 ± 0.096 0.233
Table 2. Simple and multiple linear regression coefficients between faecal SCFA and metabolic parameters 
in fasting state. β, standardized β coefficient + standard error of coefficient of faecal acetate, propionate and 
butyrate as dependent variable in a simple regression and multiple regression analysis adjusted for age, sex and 
BMI. M-value (n = 93), PYY (n = 107). Adj, adjusted, std standardized, E%, percentage of energy expenditure, 
FFA, free fatty acids, TAG, triglycerides, GLP-1, glucagon-like peptide 1, PYY, peptide YY, HOMA-IR, 
homeostatic model assessment of insulin resistance, LBP, lipopolysaccharide binding protein, IL-6, interleukin 
6, IL-8, interleukin 8, TNFα, tumour necrosis factor alpha.
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Contrary to previous human studies, faecal SCFA were not related to BMI, whereas circulating butyrate and pro-
pionate were inversely associated with BMI. Circulating plasma propionate seems to be the most reflective of its 
respective faecal concentrations, whilst faecal acetate and butyrate were not related to their respective circulating 
concentrations. In line, previous literature reports that SCFA flux into the circulation and uptake in peripheral tis-
sues rather than microbial SCFA production per se is of importance for metabolic health26–28. Our data emphasize 
the need to measure circulating SCFA in human prebiotic/probiotic intervention studies as a biomarker/mediator 
of effects on host metabolism.
To our knowledge, this is the first study providing evidence that fasting circulating SCFA are positively associ-
ated with fasting plasma GLP-1 in humans. High colonic SCFA production is linked to increased GLP-1 and PYY 
secretion through binding of SCFA to GPR41/43 on the enteroendocrine L-cell29. Further, a one-year dietary fiber 
intervention (wheat bran, 24 g/d) increased circulating SCFA concentrations accompanied by increased levels of 
GLP-1 concentrations in hyperinsulinemic participants30. Yet, there is little known about the contribution of cir-
culating SCFA to GLP-1 secretion during the fasted state. Circulating SCFA may stimulate GLP-1 secretion from 
the visceral, basolateral side of enteroendocrine L-cells as observed in isolated rat colons31. Besides enteroendo-
crine L-cells, pancreatic α-cells have been suggested to contribute to systemic GLP-1 concentrations in the fasted 
state32,33, but whether circulating SCFA act as stimuli for GLP-1 secretion warrants further investigation.
In contrast to GLP-1, we did not find an association between circulating and faecal SCFA with fasting PYY. 
This is in contrast to human and in vitro studies reporting a stimulatory effect of SCFA on PYY secretion12,34,35, 
however to what extent SCFA and/or dietary fibres contribute to fasting PYY secretion remains to be investigated. 
Although the mechanisms still remain to be elucidated, the present data indicate that, despite being the net result 
of production, uptake and tissue utilization, circulating SCFA are more directly linked to metabolic health as 
compared to faecal SCFA.
In our study population, only circulating, but not faecal SCFA were associated with fasting plasma metabolites. 
Circulating acetate was negatively associated with fasting free glycerol, an indicator of whole-body lipolysis. This 
is consistent with in vitro and human in vivo studies reporting that acetate has an anti-lipolytic effect13,36–38. This 
may be beneficial for metabolic health in the long term, since partial inhibition of adipose tissue lipolysis may 
reduce systemic lipid spillover thereby attenuating ectopic lipid accumulation39. Further, circulating propionate 
was negatively associated with fasting TAG, which might be explained by the activating effect of propionate on 
lipoprotein lipase (LPL) in adipose tissue leading to increased TAG extraction as shown in vitro40. Furthermore, 
circulating butyrate was negatively associated with fasting FFA concentrations. In vitro data about the lipolytic 
Metabolites
Circulating acetate Circulating propionate Circulating butyrate
std ß P std β adj std ß P std β adj std ß P std β adj P
FFA, μmol/L −0.032 ± 0.084 0.701 0.003 ± 0.080 0.974 −0.302 ± 0.079 0.000 −0.127 ± 0.078 0.103 −0.381 ± 0.077 <0.001 −0.306 ± 0.090 0.001
TAG, μmol/L −0.249 ± 0.081 0.003 −0.077 ± 0.081 0.340 −0.225 ± 0.081 0.006 −0.202 ± 0.078 0.010 −0.356 ± 0.078 <0.001 −0.137 ± 0.094 0.150
Glycerol, 
μmol/L −0.204 ± 0.082 0.014 −0.190 ± 0.083 0.023* −0.025 ± 0.083 0.768 0.155 ± 0.081 0.059 −0.286 ± 0.080 <0.001 −0.173 ± 0.098 0.079
Hormones
Insulin, mU/L −0.187 ± 0.079 0.019 0.003 ± 0.070 0.968 −0.234 ± 0.078 0.003 −0.066 ± 0.068 0.336 −0.406 ± 0.073 <0.001 −0.040 ± 0.082 0.625
GLP-1, pmol/L 0.402 ± 0.078 0.000 0.187 ± 0.070 0.009 0.318 ± 0.080 0.000 0.218 ± 0.068 0.002* 0.574 ± 0.069 <0.001 0.274 ± 0.081 0.001
PYY, pmol/L 0.125 ± 0.097 0.201 0.107 ± 0.107 0.317 0.080 ± 0.097 0.413 0.018 ± 0.105 0.868 0.182 ± 0.096 0.060 0.142 ± 0.126 0.263
Insulin sensitivity
M-value, mg/
kg/min −0.224 ± 0.102 0.031 −0.294 ± 0.071 <0.001 0.327 ± 0.099 0.001 0.161 ± 0.074 0.033* 0.164 ± 0.103 0.113 −0.066 ± 0.091 0.469
HOMA-IR −0.247 ± 0.079 0.002 −0.009 ± 0.067 0.892 −0.160 ± 0.080 0.047 0.007 ± 0.065 0.914 −0.461 ± 0.072 <0.001 −0.054 ± 0.078 0.494
Glucose, 
mmol/L −0.228 ± 0.078 0.004 0.005 ± 0.066 0.939 −0.177 ± 0.078 0.025 −0.044 ± 0.064 0.499 −0.506 ± 0.068 <0.001 −0.200 ± 0.075 <0.001
Inflammatory markers
LBP, pg/ml −0.075 ± 0.088 0.399 0.038 ± 0.087 0.667 −0.262 ± 0.085 0.003 −0.117 ± 0.085 0.168 −0.330 ± 0.083 <0.001 −0.116 ± 0.102 0.254
IL-6, pg/ml −0.298 ± 0.077 0.000 −0.098 ± 0.070 0.163 −0.177 ± 0.079 0.027 −0.027 ± 0.053 0.690 −0.406 ± 0.073 0.000 −0.021 ± 0.082 0.803
IL-8, pg/ml −0.079 ± 0.080 0.324 0.024 ± 0.086 0.778 0.126 ± 0.079 0.113 0.164 ± 0.084 0.051 −0.023 ± 0.080 0.775 0.185 ± 0.100 0.067
TNF-α, pg/ml −0.296 ± 0.076 0.000 −0.105 ± 0.076 0.168 −0.095 ± 0.079 0.232 −0.048 ± 0.075 0.523 −0.330 ± 0.075 <0.001 −0.047 ± 0.089 0.598
Substrate Oxidation
Fat, E% −0.156 ± 0.084 0.065 −0.021 ± 0.086 0.812 −0.117 ± 0.084 0.167 −0.052 ± 0.085 0.543 −0.317 ± 0.080 <0.001 −0.138 ± 0.101 0.172
CHO, E % 0.074 ± 0.087 0.396 0.159 ± 0.094 0.094 −0.092 ± 0.087 0.291 −0.167 ± 0.092 0.072 0.002 ± 0.087 0.986 0.047 ± 0.111 0.672
Table 3. Simple and multiple linear regression coefficients between circulating SCFA and metabolic parameters 
in fasting state. β, standardized β coefficient + standard error of coefficient of fasting circulating acetate, 
propionate and butyrate as dependent variable in a simple regression and multiple regression analysis adjusted 
for age, sex and BMI. M-value (n = 93), PYY (n = 107). Adj, adjusted, std standardized, E%, percentage of 
energy expenditure, FFA, free fatty acids, TAG, triglycerides, GLP-1, glucagon-like peptide 1, PYY, peptide YY, 
HOMA-IR, homeostatic model assessment of insulin resistance, LBP, lipopolysaccharide binding protein, IL-6, 
interleukin 6, IL-8, interleukin 8, TNFα, tumour necrosis factor alpha.
5Scientific RepoRtS |         (2019) 9:12515  | https://doi.org/10.1038/s41598-019-48775-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
effect of butyrate are contradictive showing pro- and antilipolytic effects of butyrate in white adipose tissue mod-
els38,41. Thus, circulating SCFA may be negatively related to systemic glycerol or FFA and/or TAG suggesting that 
increased circulating SCFA may reduce systemic lipid overflow with a potential beneficial effect on ectopic lipid 
accumulation and insulin sensitivity.
Nevertheless, with respect to markers of insulin sensitivity, neither fasting circulating nor faecal SCFA were 
related to fasting insulin or HOMA-IR in the total study population. Yet, fasting circulating butyrate, but not 
acetate and propionate, was negatively associated with fasting glucose. This is consistent with rodent studies 
showing that butyrate administration may have glucose lowering effects and may improve insulin sensitivity in 
the postprandial state42,43. In obesity, insulin resistance and T2DM, the abundance of butyrate-producing bacteria 
is reduced, which may explain to some extent the inverse association between circulating butyrate and fasting 
glucose in our study44–46.
In the subgroup analysis including prediabetic individuals with obesity, circulating acetate was negatively 
associated with peripheral insulin sensitivity. This is in contrast with previous rodent studies reporting a ben-
eficial role of acetate on insulin sensitivity34 and with two small-scale human cross-sectional studies including 
obese women or morbidly obese individuals reported either none or a positive association of circulating acetate 
and insulin sensitivity measured via hyperinsulinemic-euglycemic clamp, respectively47,48. Additionally, when 
acetate is administered colonically, overweight participants showed increases in fasting fat oxidation, energy 
expenditure, and PYY secretion12,13, reflective of positive effects on metabolic health. Interestingly, a kinetic 
study showed that intravenously infused acetate remains longer in the circulation in individuals with T2DM 
suggesting a disturbed acetate tissue uptake and metabolism in the context of metabolic disorders34. Further, 
exogenous and endogenous acetate production but not colonic acetate absorption differed between hyperin-
sulinemic and normoinsulinemic individuals after rectal infusion of sodium-acetate37,49,50. Thus, our findings 
may reflect an altered endogenous acetate metabolism rather than an altered microbial-derived acetate pro-
duction in metabolically compromised individuals. In contrast to fasting circulating acetate, fasting circulating 
propionate was positively associated with clamp-derived insulin sensitivity. Propionate has been reported to 
stimulate glucose uptake in 3T3-L1 adipocytes and C2C12 skeletal muscle cells in vitro and improve insulin 
sensitivity (HOMA-IR) in mice fed a high fat diet51,52. Possible mechanisms include an increase in peripheral 
glucose uptake via increased GPR41 stimulation, suppression of hepatic de novo lipogenesis and increase for-
mation of beneficial odd chain fatty acids in the liver53.
The main limitation of our study is the cross-sectional design, which limits causal suppositions. Further, we 
cannot account for endogenous SCFA production, splanchnic and liver extraction or tissue utilization in this 
study54,55. Secondly, measures of GLP-1 and SCFA in the postprandial state would have been valuable. However, 
the study’s major strength is the availability of faecal and fasting circulating SCFA in combination with metabolic 
markers in a relatively large cohort with a broad range of BMI and metabolic health status. This enabled us to 
investigate the relationship between faecal and fasting circulating SCFA concentrations with markers of lipid and 
energy metabolism as well as insulin sensitivity measured by the gold standard hyperinsulinemic-euglycemic 
clamp. For the first time, we confirmed that fasting circulating but not faecal SCFA were related to whole-body 
lipolysis, fasting GLP-1 and insulin sensitivity in the fasted state. Furthermore, our study calls for urgently needed 
mechanistic studies in humans concerning the relationship between SCFA, GLP-1 secretion and lipid metabolism.
In conclusion, our data show that circulating but not faecal SCFA are linked to circulating GLP-1 concentra-
tions, whole-body lipolysis and peripheral insulin sensitivity in humans. Of note, this highlights that circulating 
SCFA are more directly linked to metabolic health parameters. Therefore, our data indicate the need to measure 
circulating SCFA as a biomarker/mediator of effects on host metabolism in future human prebiotic/probiotic 
intervention studies. This may provide interesting leads for future research, which should aim to modulate the 
SCFA availability in the systemic circulation and its impact on peripheral tissue function
Methods
Study participants. This cross-sectional analysis included 160 Caucasian men and women aged 20–70 
years with a BMI between 19.2 and 41.0 kg/m2 from the general population in the vicinity of Maastricht, The 
Netherlands during August 2013 and December 2016. Individuals had normoglycemia, impaired fasting glu-
cose (IFG, ≥5.6 mmol/L) and/or impaired glucose tolerance (IGT, 2 hour plasma glucose of 7.8–11 mmol/L after 
75 g oral glucose challenge) according to the diagnostic criteria of the American Diabetes Association, 201056. 
Eligibility of the participants was assessed via a general health questionnaire, medical history and anthropometry 
during an intitial screening visit. Exclusion criteria were as follows: use of antibiotics, prebiotics, or probiotics 
3 months before the study, diagnosis of T2DM, gastrointestinal or cardiovascular diseases, abdominal surgery, 
participants with life expectancy shorter than 5 years and participants following a hypocaloric diet. Participants 
did not use β-blockers, lipid- or glucose-lowering drugs, anti-oxidants, or chronic corticosteroids. All protocols 
were reviewed and approved by the local Medical Ethical Committee (MUMC+) and conducted in accordance 
with the Declaration of Helsinki (revised version, October 2008, Seoul, South Korea). Written informed consent 
was obtained from all participants.
Study design. This cross-sectional analysis included metabolic parameters as well as faecal and fasting circu-
lating SCFA concentrations of previously performed intervention studies12,13,57–59. In the present study, we collated 
and analyzed study data at baseline and thus prior to the respective interventions. In all studies, sample collection 
was performed after an overnight fast, and measurements were conducted according to the same standard oper-
ating procedures. Two days prior to the baseline investigation day, participants were asked to refrain from intense 
physical activity and alcohol consumption, and to collect a faecal sample. In the evening before the investigation 
day, the participants consumed a standardized low-fiber meal.
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Used data sets. The data set included baseline data from the following intervention human in vivo studies. 
These include an intervention study in prediabetic, overweight-obese individuals on the effect of antibiotics on 
insulin sensitivity (Clinical trial No. NCT02241421) (3), an intervention study in prediabetic, overweight-obese 
individuals on the effect of dietary fiber (galacto-oligosaccharides) on insulin sensitivity (Clinical trial No. 
NCT02271776) (4), an intervention study in normoglycemic, normal to overweight individuals on the effect of 
dietary fibers on gastrointestinal transit (Clinical trial No. NCT02491125) (5), and lastly two acute studies inves-
tigating the effect of different mixtures of SCFA in normoglycemic, overweight to obese individuals on human 
substrate and energy metabolism (Clinical trial No. NCT01826162 (6), Clinical trial No. NCT01983046 (7)).
Baseline investigation day. After an overnight fast (>10 h), participants came to the laboratory by car or 
public transport. Anthropometry was measured including height, weight and waist to hip ratio. After inserting 
a cannula into the antecubital vein, blood samples were taken to measure plasma metabolites, hormones and 
inflammatory markers in the fasted state. After the blood sampling, participants were in a resting, half-supine 
position and fasting substrate oxidation was measured for 30 min using an open circuit ventilated hood sys-
tem (Omnical, MUMC+, Maastricht, the Netherlands). Fat and carbohydrate oxidation were calculated accord-
ing to the equations of Weir and Frayn60,61, assuming that protein oxidation accounted for 15% of total energy 
expenditure.
Hyperinsulinaemic-euglycaemic clamp. Peripheral insulin sensitivity was determined in a subgroup of 
overweight/obese, prediabetic individuals via hyperinsulinaemic-euglycemic clamps as previously described57,58. 
In short, a cannula was inserted into an antecubital vein for infusion of glucose and insulin. To measure blood 
glucose, a second cannula was inserted into a superficial dorsal hand vein, which was arterialized by placing the 
hand into a hotbox (~50 °C). A priming dose of insulin infusion (Actrapid, Novo Nordisk, Gentofte, Denmark) 
was administered during the first ten min (t0–t10 min) and insulin infusion was thereafter continued at 40 mU/
m2/min for 2 h (t10–t120 min). By variable infusion of a 20% glucose solution, plasma concentrations were main-
tained at 5.0 mmol/L. Peripheral insulin sensitivity (M-value, mg*(kg*min)−1 was calculated from the mean 
glucose infusion rate during the steady-state of the clamp (last 30 min, stable blood glucose concentration at 
5.0 mmol/L)62. A high M-value represents high insulin sensitivity (i.e., more glucose needs to be infused to main-
tain euglycemia during insulin infusion).
Analysis of faecal and circulating ScfA. Faecal samples were collected at home and stored in the sub-
jects’ freezer at −20 °C maximum of two days before the baseline investigation day, transported on dry ice, and 
stored on arrival at the university at −80 °C. Faecal acetate, propionate, and butyrate were measured by gas 
chromatography-mass spectrometry (Dr. Stein and Colleague Medical Laboratory, Mönchengladbach, Germany) 
as previously described63. Plasma sample preparation for circulating SCFA analysis were performed as reported 
previously64. In short, deproteinization was performed by mixing 1 part plasma (v/v) with 2 parts methanol acid-
ified with 1.5 mmol/l hydrochloric acid. Subsequently, samples were vortex-mixed vigorously and immediately 
centrifuged at 50000 × g in a model Biofuge Stratos (Hereaus, Dijkstra Vereenigde, Lelystad, the Netherlands) 
for 15 min. at 4 °C. 100 μl aliquots of the clear plasma supernatant were transferred into glass micro-insert vials 
and stored in the Combi-Pal until analysis. Samples were calibrated against external standards. The reversed 
phase separation was performed on a X-select ODS 2.5 µm column (150 mm × 2.1 mm I.D., Waters, Breda, the 
Netherlands), mounted in a Mistral Spark column oven (Separations, H.I. Ambacht, the Netherlands), set to 
45 °C. Samples were completely separated from other components into the individual SCFA in a 25 min. gradi-
ent cycle between an aqueous 1 mmol/l solution of sulfuric acid and ethanol. Post-column, the solvent pH was 
enhanced to about 9, by mixing with 150 mmol/l ammonia in ethanol to maximize negative ionization. Samples 
were processed using a Combi-PAL sample processor (Interscience, Breda, the Netherlands) with Peltier chilled 
sample storage compartments set to 10 °C. The system was equipped with a 50 µl sample loop. Separated SCFA 
were detected using a model LTQ XL linear ion trap mass spectrometer (Thermo Fisher Scientific, Breda, the 
Netherlands), equipped with an ion-max electrospray probe. The MS was operated in MS-MS full scan negative 
mode.”
Blood collection and biochemical analysis. Blood was collected in pre-chilled EDTA tubes (0.2 mol/L 
EDTA; Sigma, Dorset, UK) for SCFA, insulin, glucose, FFA, TAG, free glycerol, LBP, GLP-1, TNF-α, IL-6 and 
IL-8 analyses during fasting conditions. For GLP-1 and PYY analysis, 20 μl of dipeptidyl peptidase-IV inhibitor 
(Milipore Merck, Billerica, MA, USA) was added to EDTA and Aprotinin (Becton Dickinson, Eysins, Switzerland) 
tubes, respectively. Samples were centrifuged at 3500 g, 4 °C for 10 minutes; plasma was aliquoted and directly 
snap-frozen in liquid nitrogen and stored at −80 °C until analysis. Plasma glucose concentrations were determined 
using commercially available reagent kit (Glucose Hexokinase CP, Horiba ABX Pentra, Montpellier, France) 
involving a two-step enzymatic reaction with hexokinase followed by Glucose-6-phosphate-dehydrogenase 
resulting in D-gluconate-6-phosphate. The colorimetric reaction was measured using an automated spectropho-
tometer (ABX Pentra 400 autoanalyzer, Horiba ABX Pentra). Plasma FFA concentrations were measured using a 
commercially available kit (NEFA-HR(2) assay, Wako, Sopachem BV, Ochten, the Netherlands) with a two-step 
enzymatic reaction involving acylation of Coenzyme(Co) A followed by acyl-CoA oxidase resulting in the pro-
duction of hydrogen peroxide as substrate that in the presence of peroxidase yields a blue purple pigment, meas-
ured with a colorimetric reaction using an automated spectrophotometer (ABX Pentra 400 autonalyzer, Horiba 
ABX Pentra). Plasma TAG were determined using a commercially available kit (Triglycerides CP, Horiba ABX 
Pentra) based on enzymatic reactions involving lipoprotein lipase, glycerolkinase and glycerol-3-phosphate oxi-
dase resulting in the production of hydrogen peroxide as substrate of a colorimetric reaction measured using the 
automated spectrophotometer (ABX Pentra 400 autonalyzer, Horiba ABX Pentra). Plasma glycerol was measured 
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after precipitation with an enzymatic assay (Enzytec TM Glycerol, Roche Biopharm, Basel, Switzerland) involving 
phosphorylation of glycerol to L-glycerol-3-phosphate by glycerokinase and the colorimetric reaction is meas-
ured using an automated spectrophotometer (Cobas Fara, Roche Diagnostics, Basel, Switzerland). Plasma insulin 
was determined with a commercially available radioimmunoassay (RIA) kit (HI-14K Human Insulin specific 
RIA, Millipore Merck) according to the manufacture’s protocol. Plasma IL 6, IL-8 and TNF-α were determined 
with an commercialy available enzyme-linked immunosorbent assay (ELISA) kit (Human Proinflammatory II 
4-Plex Ultra-Sensitive kit, Meso Scale Diagnostics, MD, USA). Plasma samples were assayed for total GLP-1 
immunoreactivity using an antiserum that reacts equally with intact GLP-1 and the primary (N-terminally trun-
cated) metabolite as previously described65. PYY concentrations were determined using a commercially available 
RIA kit (Human PYY (3–36) Specific RIA, Millipore Merck). Plasma LBP was measured as previously described66. 
In short, plates (Greiner Mocrolon 600 high binding; Sigma Aldrich, St. Louis, MO) were coated with polyclonal 
anti-human LBP antibodies. Diluted plasma samples (1:5000) and a standard dilution series with recombinant 
LBP were added to the plate. Detection occurred with a biotinylated polyclonal rabbit anti-human LBP IgG, fol-
lowed by peroxidase-conjugated streptavidin and substrate. The detection limit for the LBP assay was 200 pg/ml.
Statistical analysis. Normality of data was assessed with the Gaussian distribution and Kolmogorov-Smirnov 
procedure, and ln or Z-score transformation was used if assumption of normality was not met. HOMA-IR was 
calculated as previously described67. In case of missing data, the participant was excluded from the analysis. 
Multicollinearity was checked using variance inflation factor index <10. First, we used simple linear regression to 
investigate the associations between faecal and circulating concentrations of acetate, propionate and butyrate (as 
dependent variables) and metabolic parameters (as independent variables) i.e. insulin sensitivity (M-value), insulin 
resistance (HOMA-IR), circulating glucose, insulin, circulating lipids (TAG, FFA and glycerol), circulating inflam-
matory markers (IL-6, IL-8, TNF-α and LBP) and fasting substrate oxidation. Subsequently, we used multiple linear 
regression to test whether the associations between faecal and circulating SCFA and the aforementioned metabolic 
parameters were independent of the covariates sex, age and BMI. All data were analysed using SPSS 22.0 (IBM, 
Armok, U.S.) with significance set at P < 0.05.
ethics approval. The studies summarized in this manuscript were approved by the Medical Ethics 
Committee of Maastricht University Medical Centre and was conducted according to the ethical standards of the 
Helsinki Declaration and in accordance with the Medical Research Involving Human Subjects Act (WMO). All 
patients provided verbal and written informed consent.
Data Availability
The used intervention study data are unsuitable for public deposition due to ethical restrictions and privacy of 
participant data. Data are available from these studies for any interested researcher who meets the criteria for 
access to confidential data. Prof. Ellen Blaak (e.blaak@ maastrichtuniversity.nl) may be contacted to request study 
data.
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